NEWS
News & Events
FDA Offers Docs Guidance on Rosiglitazone as Safety Review Nears Completion
Senate Committee Critical of Agency, GSK(02/25/2010) -- The FDA is recommending that patients continue taking the diabetes medication rosiglitazone, unless told otherwise by their physicians, as the agency continues to look at the risks and benefits of using rosiglitazone to treat type 2 diabetes. Meanwhile, the Senate Committee on Finance and drug manufacturer GlaxoSmithKline, or GSK, are debating the safety of the drug. More
|
> back to News |
